Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]RadioEVs (also known as [177Lu]RadioExo) is a preclinical nanotheranostic agent consisting of goat milk-derived extracellular vesicles (EVs) radiolabeled with Lutetium-177 (177Lu) via passive membrane loading or DOTA-mediated chelation. Developed by the Instituto de Investigación Sanitaria Gregorio Marañón and the Universidad Carlos III de Madrid, this radiopharmaceutical leverages the natural tumor tropism and biocompatibility of milk-derived exosomes to deliver targeted beta-radiation directly to cancer cells. In preclinical studies, [177Lu]RadioEVs demonstrated efficient tumor-targeted internalization and dose-dependent cytotoxicity in various cancer cell lines, including glioblastoma (U87MG), breast cancer (MDA-MB-231), colorectal cancer (HCT116), pancreatic cancer (PANC1), and cutaneous melanoma, while serving as a SPECT imaging agent for real-time tumor localization.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | Preclinical | Active |
| colorectal cancer (CRC) and precursor lesions | Preclinical | Active |
| glioblastoma, IDH-wildtype | Preclinical | Active |
| melanoma | Preclinical | Active |
| pancreatic cancer and precursor lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [177Lu]RadioEVs.
Work on [177Lu]RadioEVs? Claim this page to correct or add information. Claim this page